"I believe here is a link to the law below. Also note humira was first approved in 2002 and they have extended exclusivity in US until 2023, 21 years after approval using a series of patents issued after approval if I remember correctly."

With the recent patent for monotherapy valid until 2035, this strategy might work for CYDY too.
https://patents.justia.com/assignee/cytodyn-inc

But since patent law is tricky and since I have no idea how strong CYDYs (future) patents are, I'll simply assume generics will enter in 2032 just to be very conservative...